Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


What US FDA’s ‘Emerging Signals’ Guidance Means For Medical Device Manufacturers

Executive Summary

Thanks to the relatively new agency guidance document related to emerging medical device signals, consumers and health-care providers will receive more prompt and frequent notifications of potential product risks. But there is potential ambiguity for every stakeholder involved, Michael Good of Stericycle ExpertSOLUTIONS explains in this Medtech Insight guest column.


Related Content

Q4 Recalls Snapshot: Numbers Dip Slightly But Remain High; Sterility Troubles Bubble To Surface
FDA To Release Only Confirmed New Device Risk Data It Sees, Says Final Emerging Signals Guidance
Q3 Recalls Snapshot: Numbers Continue To Rise; Software, Mislabeling Remain Top Reasons For A Recall





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts